Please use this identifier to cite or link to this item:
|Title:||In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma|
Castro, Paulo J. G.
Fonseca, António M.
Reis, R. M.
Neves, Isabel C.
|Publisher:||Royal Society of Chemistry|
|Journal:||Royal Society of Chemistry Advances|
|Citation:||Martinho, O., Vilaca, N., Castro, P. J. G., Amorim, R., Fonseca, A. M., Baltazar, F., . . . Neves, I. C. (2015). In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. Rsc Advances, 5(36), 28219-28227. doi: 10.1039/c5ra03871e|
|Abstract(s):||Zeolites Y (faujasite) and MOR (mordonite) were used as hosts for temozolomide (TMZ), a current good-standard chemotherapeutic agent used in the treatment of glioblastoma brain tumors. TMZ was loaded into zeolites by liquid-phase adsorption at controlled pH. FTIR, 1H NMR, MS, SEM, UV/vis and chemical analysis demonstrated the successful loading of TMZ into zeolite hosts. The hydrolysis of TMZ in MTIC (TMZ metabolite) after the preparation of drug delivery systems (DDS) was observed in simulated body fluid. The effect of zeolites and DDS were evaluated on the viability of glioblastoma cell lines. Unloaded Y zeolite presented toxicity to cancer cells in contrast to MOR. In accordance, the best results in potentiation of the TMZ effect was obtained with MOR. We found that mordonite loaded with 0.026 mmol of TMZ was able to decrease the half maximal inhibitory concentrations (IC50) at least 3-fold in comparison to free temozolomide both in vitro and in vivo.|
|Appears in Collections:||ICVS - Artigos em Revistas Internacionais com Referee|